Unparalleled Success Rate in FFPE Samples
Cancer genomic profiling can be challenging for patients with limited tissue sample, especially in cancer types such as lung cancer where small biopsy samples coupled with low tumor cellularity are the norm. By performing macrodissection and utilizing our expertise in handling FFPE samples, ACT Genomics is able to offer high success rate in FFPE and provide more comprehensive information on copy number variation (CNV) and mutations, with a small amount of specimens.
Wider Coverage of Biomarkers to Predict Response to Immune Checkpoint Inhibitors (ICIs)
ACTOnco®+ comprehensive genomic profiling, ACT Genomics’ flagship panel, covers tumor mutational burden (TMB), microsatellite instability (MSI) status and immune-related genes to provide a more accurate prediction of ICI responses.
- ACTOnco®+ TMB Strongly Correlates with WES TMB
Conducting whole exome sequencing (WES) is considered the gold standard for TMB assessment. However, this is often not feasible in clinical practice due to significant costs and long turnaround time. ACTOnco®+ is capable of providing estimated TMB data that is highly correlated with the TMB measured with WES across different tumor types. (Friends of Cancer Research (FoCR): Tumor Mutational Burden (TMB); Washington DC; 2018 May 10)
- Covers Genes in Immune-Related Pathways
In addition to TMB and MSI, ACTOnco®+ also provides genomic alterations of genes known to confer sensitivity or lack of benefit to ICI such as PTEN, STK11, JAK1/2, EGFR, B2M, MDM2/MDM4, PBRM1, SERPINB3, SERPINB4, and antigen processing and presentation genes.
1-on-1 Report Consultation & User-friendly Report
For every report, ACT Genomics provides one-on-one report consultation for ordering physician. Our user-friendly reports offer clinically significant insights through logically-organized content and intuitive graphics.